Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 12/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CNOT7 | Q9UIV1 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5436730 | 1.00 | CASR (0.53) | CASRKDM4EHTTSMN1; SMN2LMNA | |
| SCHEMBL5444290 | 1.00 | CASR (0.53) | CASRKDM4EHTTSMN1; SMN2LMNA | |
| SCHEMBL5441128 | 0.99 | CASR (0.53) | CASRKDM4EHTTSMN1; SMN2LMNA | |
| SCHEMBL5438968 | 0.96 | CASR (0.54) | CASRKDM4EHTTSMN1; SMN2LMNA | |
| SCHEMBL5443930 | 0.91 | CASR (0.56) | CASRKDM4ELMNAHPGDMEN1 | |
| SCHEMBL5435362 | 0.88 | CASR (0.55) | CASRKDM4EHTTSMN1; SMN2LMNA | |
| SCHEMBL5436815 | 0.88 | CASR (0.55) | CASRKDM4EHTTSMN1; SMN2LMNA | |
| SCHEMBL5443722 | 0.87 | CASR (0.56) | CASRMEN1KMT2ANR1I2GFER | |
| SCHEMBL5436407 | 0.84 | CASR (0.51) | CASRTP53MEN1KMT2ANR1I2 | |
| SCHEMBL5441088 | 0.82 | CASR (0.52) | CASRKDM4ESMN1; SMN2TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270446-A1 | Reversed Pyrimidinone Compounds as Calcilytics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-22 | — | — | US | claimed |
| EP-1809611-A1 | REVERSED PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2007-07-25 | — | — | EP | claimed |
| WO-2006041968-A1 | REVERSED PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | claimed |
| US-20070270446-A1 | Reversed Pyrimidinone Compounds as Calcilytics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070270446-A1 | Reversed Pyrimidinone Compounds as Calcilytics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070270446-A1 | Reversed Pyrimidinone Compounds as Calcilytics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-22 | — | — | US | disclosed |
| EP-1809611-A1 | REVERSED PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006041968-A1 | REVERSED PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270446-A1 | Reversed Pyrimidinone Compounds as Calcilytics | PTMS, CALCR, TYMP | CASR 60/4885KDM4E 3442/4885HTT 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.